Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463209 | 1.00 | BRPF1 (0.47) | BRPF1BRD4AVPR1APIM1MEN1 | |
| Hydrochloric Acid SCHEMBL23882148 | 0.98 | BRPF1 (0.46) | BRPF1BRD4AVPR1APIM1MEN1 | |
| SCHEMBL2631721 | 0.88 | MEN1 (0.46) | BRPF1BRD4AVPR1APIM1MEN1 | |
| SCHEMBL12387711 | 0.83 | BRPF1 (0.41) | BRPF1BRD4AVPR1APIM1MEN1 | |
| SCHEMBL30738818 | 0.78 | BRPF1 (0.50) | BRPF1BRD4AVPR1AMEN1KMT2A | |
| SCHEMBL4013751 | 0.78 | BRPF1 (0.50) | BRPF1BRD4AVPR1AMEN1KMT2A | |
| SCHEMBL30379824 | 0.77 | KDM4E (0.54) | BRD4MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL28833094 | 0.77 | BRD4 (0.41) | BRPF1BRD4AVPR1APIM1MEN1 | |
| SCHEMBL14497763 | 0.76 | MEN1 (0.49) | BRPF1BRD4AVPR1APIM1MEN1 | |
| SCHEMBL3311949 | 0.75 | AVPR1A (0.40) | BRPF1BRD4AVPR1APIM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116199675-A | Rhodamine fluorescence quenching agent and synthesis and application thereof | 中国科学院大连化学物理研究所 | 2023-06-02 | — | — | CN | claimed |
| WO-1999065865-A1 | NOVEL 3,4-DIAMINOPHENOL DERIVATIVES AND THEIR USE | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1999-12-23 | — | — | WO | claimed |
| WO-1999065891-A1 | NOVEL 2,4-DIAMINOPHENOL DERIVATIVES AND THE USE THEREOF | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1999-12-23 | — | — | WO | claimed |
| EP-0257583-B1 | PROCESS FOR ORTHO-CYANATION OF PHENOLS OR PHENYLAMINES | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-01-08 | — | — | EP | claimed |
| EP-0266849-B1 | PROCESS FOR INTRODUCING A THIOCARBOXYLIC ESTER GROUP AT THE ORTHO-POSITION OF PHENOLS OR PHENYLAMINES | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-03-13 | — | — | EP | claimed |
| US-4857645-A | Process for introducing a thiocarboxylic ester group at the orthoposition of phenols or phenylamines | SHIONOGI & CO., LTD. (JP) | 1989-08-15 | — | — | US | claimed |
| US-4774331-A | THIOCYANATION IN PRESENCE OF BORON TRIFLUORIDE | SHIONOGI & CO., LTD. (JP) | 1988-09-27 | — | — | US | claimed |
| EP-0266849-A1 | Process for introducing a thiocarboxylic ester group at the ortho-position of phenols or phenylamines | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-05-11 | — | — | EP | claimed |
| EP-0257583-A1 | Process for ortho-cyanation of phenols or phenylamines | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-03-02 | — | — | EP | claimed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024123991-A1 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-1999065891-A1 | NOVEL 2,4-DIAMINOPHENOL DERIVATIVES AND THE USE THEREOF | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1999-12-23 | — | — | WO | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| US-5322842-A | Tricyclic benzodiazepine derivates, their preparation, and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-21 | — | — | US | disclosed |
| EP-0544909-A1 | TRICYCLIC BENZODIAZEPINE DERIVATES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992003438-A1 | TRICYCLIC BENZODIAZEPINE DERIVATES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-05 | — | — | WO | disclosed |
| US-4576954-A | Anti-rheumatic 5-(substituted amino)-1,2-dithiol-3-one compounds and their use | PHONE-POULENC SANTE (FR) | 1986-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | BRPF1 2325/4885BRD4 611/4885AVPR1A 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.